Physician profile
Daniel Lemor
NPI 1275950115
$4,719.59
in general payments reported to CMS, 2019-2025
21 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $324 · 2022: $150 · 2023: $142 · 2024: $689 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Travel and Lodging: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.12 |
| Travel and Lodging | $1,952.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $2,252.01 | 2025 | |
| Sun Pharmaceutical Industries INC. | $707.12 | 2021-2025 | Cequa, Xelpros, Bromsite |
| Bausch & Lomb Americas INC. | $239.67 | 2025 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $236.97 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $179.43 | 2021 | |
| Harrow Eye, LLC | $152.43 | 2025 | Vevye |
| Glaukos Corporation | $135.21 | 2025 | |
| Astellas Pharma Global Development | $129.72 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $126.71 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $126.08 | 2023-2025 | |
| Alcon Vision LLC | $97.78 | 2025 | Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $96.14 | 2020-2023 | |
| Eyevance Pharmaceuticals LLC | $36.86 | 2020-2021 | |
| Akorn Operating Company LLC | $32.94 | 2021 | |
| Biotissue Holdings INC. | $30.28 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.26 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $27.66 | 2025 | Dextenza |
| Allergan, INC. | $27.42 | 2020 | |
| Mallinckrodt Hospital Products INC. | $23.65 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lemor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.